PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (Nasdaq:BJCT), a leading developer of needle-free drug delivery systems, today announced that the Biojector®2000 (“B2000”) needle-free system is being used in an Inactivated Polio Vaccine (“IPV”) study in Oman. The study is being conducted by the Oman Health Ministry’s Department of Communicable Disease Surveillance and Control (“DCDSC”), the World Health Organization (“WHO”) and PATH.
